Patents by Inventor P. Jeffrey Conn

P. Jeffrey Conn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11008335
    Abstract: Disclosed herein are pyrido[3?,2?:4,5]thieno[2,3-d]pyridazin-8-amine and thieno[2,3-c:4,5-d?]dipyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: May 18, 2021
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, Darren W. Engers, P. Jeffrey Conn, Sean R. Bollinger, Julie L. Engers
  • Publication number: 20210130348
    Abstract: Described are positive allosteric modulators of muscarinic acetylcholine receptor M1 (mAChR M1), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating neurological disorders, psychiatric disorders, or a combination thereof.
    Type: Application
    Filed: December 15, 2020
    Publication date: May 6, 2021
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Katrina A. Bollinger, Darren W. Engers, Anna L. Blobaum, Julie L. Engers, Jerri M. Rook
  • Patent number: 10968227
    Abstract: Isoquinoline ether compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: April 6, 2021
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Andrew Felts, Anna L. Blobaum
  • Patent number: 10961253
    Abstract: Disclosed herein are pyrido[3?,2?:4,5]thieno[3,2-d]pyrimidine and pyrimido[4?,5?:4,5]thieno[2,3-c]pyridazine compounds, which may be useful as positive allostenc modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: March 30, 2021
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, Darren W. Engers, P. Jeffrey Conn, Katrina A. Bollinger, Rory Capstick, Paul Spearing, Sean R. Bollinger
  • Patent number: 10934276
    Abstract: Disclosed herein are 2,4-dimethylquinoline-6-carboxamide compounds and 3,4-dimethylcinnoline-6-carboxamide compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4(mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: March 2, 2021
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Julie L. Engers, Madeline F. Long
  • Patent number: 10927126
    Abstract: Disclosed herein are thieno[2,3-b:5,4-c?]dipyridin-8-amine and pyrido[4?,3?:4,5]thieno[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: February 23, 2021
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Alison R. Gregro, Kayla Temple, Paul K. Spearing, Madeline F. Long, Julie L. Engers
  • Patent number: 10899759
    Abstract: Described are positive allosteric modulators of muscarinic acetylcholine receptor M1(mAChR M1), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating neurological disorders, psychiatric disorders, or a combination thereof.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: January 26, 2021
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Katrina A. Bollinger, Darren W. Engers, Anna L. Blobaum, Julie L. Engers, Jerri M. Rook
  • Publication number: 20200392117
    Abstract: Disclosed herein are substituted 2-azaspiro[3.3]heptane compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.
    Type: Application
    Filed: December 20, 2018
    Publication date: December 17, 2020
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Aaron M. Bender, Logan A. Baker
  • Publication number: 20200369666
    Abstract: Disclosed herein are octahydropyrrolo[3,4-b]pyrrole compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.
    Type: Application
    Filed: August 8, 2018
    Publication date: November 26, 2020
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Kayla J. Temple
  • Publication number: 20200369650
    Abstract: Disclosed herein are 3-azabicyclo[3.1.0]hexan-6-amine compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.
    Type: Application
    Filed: February 1, 2019
    Publication date: November 26, 2020
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Julie L. Engers, Aaron M. Bender
  • Publication number: 20200339547
    Abstract: Disclosed herein are substituted hexahydro-1H-cyclopenta[c]pyrrole compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.
    Type: Application
    Filed: October 31, 2018
    Publication date: October 29, 2020
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Kayla J. Temple
  • Publication number: 20200323857
    Abstract: Disclosed herein are tricyclic compounds, including 3-(difluoromethyl)-4-methylpyrimido[4?,5?:4,5]thieno[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.
    Type: Application
    Filed: December 5, 2018
    Publication date: October 15, 2020
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Julie L. Engers
  • Publication number: 20200291019
    Abstract: Indazole compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.
    Type: Application
    Filed: August 16, 2018
    Publication date: September 17, 2020
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Andrew S. Felts, Colleen M. Niswender, Rory A. Capstick, Paul K. Spearing, Sean R. Bollinger
  • Patent number: 10736898
    Abstract: Disclosed herein are tricyclic compounds, including thieno[2,3-d:4,5-d?]dipyrimidin-4-amine and pyrido[4?,3?:4,5]thieno[2,3-d]pyrimidin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: August 11, 2020
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Julie L. Engers
  • Publication number: 20200231592
    Abstract: In one aspect, the invention relates to substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M1 (mAChR M1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: March 18, 2020
    Publication date: July 23, 2020
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Michael R. Wood, Corey R. Hopkins, Bruce J. Melancon, Michael S. Poslusney, Darren W. Engers
  • Patent number: 10710997
    Abstract: Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4) of the following formula: synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: July 14, 2020
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Corey R. Hopkins, Andrew Felts, Aaron M. Bender
  • Publication number: 20200181166
    Abstract: Disclosed herein are pyrido[3?,2?:4,5]thieno[2,3-d]pyridazin-8-amine and thieno[2,3-c:4,5-d?]dipyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.
    Type: Application
    Filed: November 7, 2017
    Publication date: June 11, 2020
    Inventors: Craig W. Lindsley, Darren W. Engers, P. Jeffrey Conn, Sean R. Bollinger, Julie L. Engers
  • Publication number: 20200165232
    Abstract: Pyridine quinoline compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.
    Type: Application
    Filed: June 28, 2018
    Publication date: May 28, 2020
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Andrew S. Felts, Colleen M. Niswender, Rory A. Capstick, Paul K. Spearing, Sean R. Bollinger
  • Patent number: 10654847
    Abstract: In one aspect, the invention relates to substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M1 (mAChR M1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: May 19, 2020
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Michael R. Wood, Corey R. Hopkins, Bruce J. Melancon, Michael S. Poslusney, Darren W. Engers
  • Publication number: 20200131159
    Abstract: Described are positive allosteric modulators of muscarinic acetylcholine receptor M1 (mAChR M1), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating neurological disorders, psychiatric disorders, or a combination thereof.
    Type: Application
    Filed: October 24, 2019
    Publication date: April 30, 2020
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Aaron M. Bender